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Endothelin receptors, predommantly of the ET, type, were localized to cell bodies. processes, and varicosities of cholmergic and adrenergic 
intramural autonomic neurons that were present in primary cultures of guinea pig tracheal smooth muscle. Stimulation of the neuronal ET, receptor 
produced a tetrodotoxin-sensitive increase m the intracellular calcium concentration in neurons which was followed by contraction of the 
neighboring smooth muscle cells. These observations suggest that endothelins can induce smooth muscle contraction by means of a neuronally 
mediated mechanism. in addition to their direct actions on the smooth muscle. 
Endothelin: Receptor; Autonomic neuron; Smooth muscle; Contraction 
1. INTRODUCTION 
Endothelin (ET), discovered as a potent vasoactive 
peptide produced by cultural endothelial cells [l], is a 
family of peptides, ET-l, ET-2, and ET-3 [2,3]. 
Sarafotoxins, isolated from the venom of the snake 
Atractaspis engaddensis, possess structural features and 
pharmacological activities similar to those of ETs [4]. 
ETs and sarafotoxins exert pharmacological actions 
such as transient vasodilation and nrolonaed contrac- 
2. MATERIALS AND METHODS 
2.1. Materials 
[“SI]ET-l, [“‘IlET- and [“‘I]IRL 1620(- 74 TBqlmmol) were pur- 
chased from DuPont-New England Nuclear (Boston. MA). Authentic 
ET-1 and ET-3 (Peptide Institute Inc., Osaka, Japan), BQ-123 (Pen- 
nmsula, CA), and fura-2-acetoxymethylester (Dojin, Kumamoto, 
Japan) were obtained commercially. IRL 1620 was synthesized as 
reported previously [12]. All other chemicals used were of reagent 
grade. 
2.2. Cell preparation 
1 
tion of bronchial, intestinal, uterine, and other smooth 
muscle [5,6]. These pharmacological actions are medi- 
ated by two types of ET receptor: ET, receptor (selec- 
tive for ET-l and ET-2) [7] and ET, receptor (nonselec- 
tive) [8]. In the airway, ETs are implicated in the patho- 
genesis of asthma because inhalation of ET-l produced 
long-lasting bronchoconstriction and because ET- I 
production by the airway epithelium was higher in pa- 
tients with asthma [5,6,9]. The ET-induced bronchocon- 
striction is often associated with hypersensitivity against 
other bronchoconstrictors such as acetylcholine and 
histamine [lO.l 11. We report here a second pathway of 
ET-induced smooth muscle contraction. 
Gumea pig tracheal smooth muscle was incubated at 37°C for 1 h 
in oxygenated (95% O2 and 5% CO,) Hank’s solution containmg 200 
U/ml collagenase (Worthington type I), 0.5 U/ml elastase (Biozyme 
type E2) and 100 U/ml DNase (Sigma) with mild shaking (120 strokes/ 
min). The tissue was minced into smaller pieces (- 1 mm’) and then 
incubated for 2 h. The dispersed cells were suspended to a density of 
7 x IO4 cells/ml in Dulbecco’s modified Eagle’s medium (DMEM) 
containmg 10% fetal bovine serum. 50 U/ml penicillm-G, 50 &ml 
streptomycin and 0.5 mM L-glutamme on slides in 95% 0, and 5% CO2 
at 37°C for 5 to 7 days. 
2.3. Autoradiograph.~ and inlntunoc?tochentrstr~ 
The primary cultures were Incubated at 37°C for I h with 30 pM 
[“‘IlETs in the absence or presence of unlabeled ligands in 20 mM 
HEPES (pH 7.4) containing 140 mM NaCl, 4 mM KCl, 1 mM 
K>HPO,. 1 mM MgCL, 1 mM CaCl?, 10 mM o-glucose, and 0.1% 
bovine serum albumin. The slides were then fixed with 2% paraformal- 
dehyde in 0.1 M sodium phosphate (pH 7.4) for 10 min, air-dried, 
dipped mto Konica NR-M2 emulsion. and stored in the dark. After 
an exposure for 2 weeks, the slides were developed with Konidol X 
for 6 min at 20°C. Neurons were identified by staining with antibodies 
against choline acetyltransferase and tyrosine hydroxylase (Chemicon, 
CA) and with an avidinbiotinperoxidase complex stainmg kit (Vec- 
tor Labs, CA). 
Correspondence address: Y. Urade, International Research Laborato- 
ries, Ciba-Geigy Japan Limited, lo-66 Miyuki-cho, Takarazuka 665, 
Japan. Fax: (81) (797) 74 2598. 
Abbrevtatrons: ET, endothelin; DMEM, Dulbecco’s modified Eagle’s 
medium; HEPES. N-2-hydroxyethylpiperazine-N’-2-ethanesulfomc 
acid: [Ca”],, intracellular Ca” concentration. 
2.4. Meusurement of intracelluiur Cu” concentration ([Ca”],) 
The cultured cells on quartz shde-glass were incubated at 37°C for 
1.5 h with 5 PM fura-2-acetoxymethyl ester in a serum-free DMEM 
in a CO? incubator. The fura-2-loaded cells were transferred to a 
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Fig. 1. Autoradiographic detection of ETA and ET, receptors in cultured smooth muscle cells accompanied by peripheral neurons. In each pair. 
the bright-field image is on the left and the dark-field image on the right. (A) [“SI]ET-l. (B) [“SI]ET-l in the presence of BQ-123, (C) [“‘IlET-1 
in the presence of excess unlabeled ET-l, and (D to F) [“51]ET-3. Neurons were labeled with antibodies against choline acetyltransferase (E) and 
tyrosine hydroxylase (F). Bar = 20 pm. 
chamber on the stage of a Mu-1000 Ca” analyzer (INTER DEC, 
Osaka, Japan). The [Ca”], change was monitored fluorimetrically with 
an emission wavelength at 5 10 nm and excitation wavelengths at 340 
and 380 nm, and recorded at 33-ms intervals to video tape for image 
analyses. Two wavelength ratio images of mdividual cells were then 
digitized offline to calculate [Ca”], with a standard curve. 
network of neuronal processes that often were seen in 
the periphery of smooth muscle cell colonies. As as- 
sessed immunocytochemically, about 20% of the neu- 
rons reacted with anti-choline acetyltransferase anti- 
body and about 60% with anti-tyrosine hydroxylase an- 
tibody; the remaining neurons were neither cholinergic 
3. RESULTS AND DISCUSSION 
nor adrenergic. 
Both smooth muscle cells and neurons were labeled 
with silver grains by autoradiography after incubation 
with 30 pM [‘“‘IlET-1, a ligand that binds to ET, and 
ET, receptors (Fig. 1A). In the presence of 10 PM BQ- 
123, an ETA-antagonist [13], neurons were densely la- 
In primary cultures of guinea pig tracheal smooth 
muscle, intramural autonomic neurons coexisted with 
smooth muscle cells innervated by these neurons. Most 
neurons grew over smooth muscle cells and reformed a 
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Fig. 2. Time courses of [Ca”], changes in cholinergic (A, B and C) and adrenergic (E, F and G) neurons (arrowheads) and in smooth muscle cells 
(arrows) (D and H) in response to ET-3 and ET-l. Fluorescence images (left in each pair) and the corresponding bright-field images (right in each 
pair) stained for choline acetyltransferase and tyrosine hydroxylase are shown in the top. Numbers of cholinergic and adrenergic neurons showing 
[Ca”], changes imilar to those of (A and E) were 7 and 41; (B and F), 8 and 21; and (C and G), 14 and 26; respectively. No changes were seen 
in 4 cholinergic and 10 adrenergic neurons. Neurons were loaded with more fura- than smooth muscle cells producing the brighter images, however, 
the calculated [Ca*‘], did not differ significantly between the two cell types. Bar = 20 pm. 
beled with [‘*‘I]ET-1 whereas the labeling of smooth 
muscle cells was reduced greatly (Fig. 1B). A similar 
labeling pattern to that with [‘251]ET-1 plus BQ-123, was 
obtained with 30 pM [‘251]ET-3 (Fig. lD-F) or 30 pM 
[‘251]IRL 1620, a potent and highly selective ET,-ag- 
onist [ 12,141. Labeling was eliminated by an excess (200 
nM) of unlabeled ET-l (Fig. 1C). These results indicate 
that the peripheral neurons predominantly possess ET, 
receptors whereas the smooth muscle cells have ET, 
receptors. 
The ET, receptor was distributed evenly over neu- 
ronal cell bodies and their processes with varicosities 
that often spread over the muscle cells (Fig. ID). Both 
cholinergic (79 of the 152 cells) and adrenergic (288 of 
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the 446 cells) neurons expressed the ET, receptor (Fig. 
1E and F). 
We measured changes in [Ca”‘], of individual cells 
after stimulation of ET, receptors with 10 nM ET-3 or 
500 nM IRL 1620. About 90% of the 131 neurons exam- 
ined responded with [Ca’+]i increases. Cholinergic neu- 
rons (29 of the 33 cells) displayed large increases of 
[Ca”], (> 100 nM from basal concentrations of 30 to 
100 nM) within 1 min of stimulation. Adrenergic neu- 
rons (88 of the 98 cells), in contrast, showed smaller 
[Ca”], increases (- 50 nM from basal). These increases 
were followed by decline to a sustained concentration 
still elevated over basal (Fig. 2A,B,E,F), or by a return 
to the basal concentration (Fig. 2C and G). Stimulation 
of ET, receptors with 10 nM ET-l after decline to the 
plateau produced no further increase in 7 cholinergic 
(Fig. 2A) and 41 adrenergic neurons (Fig. 2E) but a 
secondary [Ca”], increase in 22 cholinergic (Fig. 2B and 
C) and 47 adrenergic neurons (Fig. 2F and G), suggest- 
ing that the latter neurons possess both ET, and ET, 
receptors. On the other hand, a second stimulation with 
ET-3, instead of ET-l, resulted in no further increase in 
[Ca”],. In the absence of extracellular calcium or after 
incubation with 300 nM tetrodotoxin for 2 min, the 
neuronal [Ca2’], responses were attenuated to a slight 
increase (< 30 nM from basal). These results indicate 
that stimulation of ET receptors leads to activation of 
neuronal signal transduction [15,16] which would be 
followed by neuronal responses including transmitter 
release and elongation or degeneration of neuronal 
processes. 
Smooth muscle cells (280 cells) showed only small 
[Ca”], increases (< 50 nM from basal concentrations of 
80 to 140 nM) by ET-3 or IRL 1620 treatment, but ET-l 
produced much larger increases (> 150 nM from rest- 
ing) (Fig. 2D and H), indicating that these cells predom- 
inantly possess ET, receptors, in agreement with the 
results of autoradiography. Tetrodotoxin did not alter 
ET-induced [Ca”], changes in the smooth muscle cells. 
While monitoring [Ca”]_ we also observed the de- 
layed contraction of smooth muscle cells near neurons 
(5 of the 74 cells) after stimulation of neuronal ET, 
receptors (Fig. 3). In the neuron, ET-3 evoked a tran- 
sient [Ca”], increase, peaking at 200 nM after 45 s (Fig. 
3B). The [Ca”], then declined to a sustained plateau of 
120 nM, a response typical of cholinergic neurons (Fig. 
t 
Fig. 3. Contraction of a smooth muscle ceil after ET-3-induced neu- 
ronal activation. Upper panel shows the time course of [CaZ’JZ changes 
in the selected area directly measured with photomultipher. Arrows 
(A to H) correspond to time for fluorescence Images (lower panel, each 
upper photo) and computer-processed [Ca”], Images (lower panel. 
each lower photo) of the cultured cells. A neuron (arrowhead m A) 
and its processes with varicosities lies m the center with a contracting 
smooth muscle cell on the left upper stde (empty arrows m A to F). 
The pseudocolor scale used for the [Ca”], images is shown at the 
bottom. 
2). The smooth muscle cell showed no increase of [Ca”], 
in response to ET-3 (Fig. 3B-F), yet it began to contract 
130 s after ET-3 addition (Fig. 3C). Stimulation with 
ET-l produced increases in [Ca”], in both the smooth 
muscle cell and the neuron after 40 s with a peak of 240 
nM for both (Fig. 3G) with recovery within 120 s (Fig. 
3H). The ET-3-induced contraction was not observed 
for smooth muscle cells far from the neuron (206 cells), 
or in the presence of tetrodotoxin (the 30 monitored 
cells near neurons). These results suggest that the con- 
traction of the smooth muscle cell was not due to non- 
specific cell damage and leakage of Ca2+ but was medi- 
ated by ET-3-induced activation of neurons followed by 
a release(s) of diffusible transmitter(s) from its varicosi- 
ties to the effector smooth muscle cell. 
Furthermore, in 4 out of 33 recording sessions, we 
observed delayed changes in the positions of neuronal 
cell bodies and varicosities after stimulation of ET, re- 
ceptors. In these cases, although we could not identify 
contracting muscle cells within the monitored area, the 
position changes are considered to be due to the con- 
traction of smooth muscle cells attached to the neuronal 
elements, which occurred outside but near the moni- 
tored area. Because autonomic neurons connect with 
smooth muscle cells in vivo more efficiently than in 
vitro. the neuronally mediated contraction is expected 
to exist in vivo. 
ET-induced contraction has been studied in terms of 
direct actions of ETs on smooth muscle [5,6]. However, 
our observations suggest an alternative pathway of ET 
actions. Similar indirect and possibly neuronally medi- 
ated actions of ETs have been observed for vasocon- 
striction in vivo after stimulation of ET, receptors [17] 
and ET-induced increases in colonic ion transport [18]. 
On the other hand, there are a few reports demonstrat- 
ing binding sites for [“‘I]ETs by autoradiography in 
several types of ganglia [19,20]. However, previous re- 
searchers did not precisely distinguish between neurons 
and non-neuronal (glial) cells in the ganglion. ET recep- 
tors predominantly of the ET, subtype are enriched in 
the central nervous system, in which the receptors are 
mainly expressed in glial cells, but not in neurons [21]. 
In this study, we simultaneously used autoradiography 
for detection of ET receptors, immunohistochemistry 
for the identification of neurons, and Cal+ monitoring 
to demonstrate the functional coupling of neuronal ET 
receptors. Therefore, this is the first report to demon- 
strate the existence of ET receptors in autonomic 
cholinergic and adrenergic neurons. Our conclusion is 
also supported by several recent reports that ETs mod- 
ulate neurotransmitter release [22-251. 
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